Iruplinalkib (WX-0593) Versus Crizotinib in ALK TKI-Naive Locally Advanced or Metastatic ALK-Positive NSCLC: Interim Analysis of a Randomized, Open-Label, Phase 3 Study (INSPIRE)
Yuankai Shi(Chinese Academy of Medical Sciences & Peking Union Medical College), Lin Wang(Suzhou Vocational Health College), Meimei Si, Weihua Yang(Shanxi Provincial Cancer Hospital), Jiuwei Cui(Jilin University), Zhehai Wang(Shandong Tumor Hospital), Ying Cheng(Jilin Province Tumor Hospital), Ruifeng Mao(Buchang Pharma (China)), Ranhua Cao(Affiliated Hospital of North Sichuan Medical College), Lingyan Li(Chinese Academy of Medical Sciences & Peking Union Medical College), Jian Zhao(Guangzhou Medical University Cancer Hospital), Xiaoyan Kang(Qilu Hospital of Shandong University), Jianhua Chen(Xinjiang Medical University), Hui Li(University of Copenhagen), Chunling Liu(Xinjiang Medical University), Donglin Wang(Shandong University), Ke Xu, Yiping Zhang(Henan Normal University), Hongbo Wu(Shandong Tumor Hospital), Runxiang Yang(Kunming Medical University), Jinlu Shan(Army Medical University), Chang-Lu Hu(Anhui Provincial Hospital), Lei Yang(Zhengzhou University), Yunpeng Liu(Shenyang Institute of Automation), Bangxian Tan(Affiliated Hospital of North Sichuan Medical College)
Cited by 40
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k